Phase II evaluation of spirogermanium in malignant melanoma: a Southwest Oncology Group Study.
D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D009942:Organometallic Compounds; D013141:Spiro Compounds; C026818:spirogermanium